The Pfizer-Allergan Deal Shouldn't Be Just About Tax Inversion – Harvard Business Review

The Pfizer-Allergan Deal Shouldn’t Be Just About Tax Inversion – Harvard Business Review
Harvard Business ReviewThe Pfizer-Allergan Deal Shouldn’t Be Just About Tax InversionHarvard Business ReviewPfizer and Allergan are set to merge in the biggest combination of the year, valued at $160 billion. It is big in terms of the total corporate assets that are being re-assigned to new owners. But is it also big in terms of the joint value that will …Germany’s Schaeuble says need to ensure tax base doesn’t erodeReutersWhat You Need To Know About Pfizer’s Tax-Driven Merger [VIDEO]Forbesall 38 news articles »
The Pfizer-Allergan Deal Shouldn’t Be Just About Tax Inversion – Harvard Business Review